Pages that link to "Q42419226"

The following pages link to Interventions to reduce weight gain in schizophrenia (Q42419226):

Displaying 38 items.

• The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements (Q22242826) (← links)
• Management of antipsychotic-related weight gain (Q24610124) (← links)
• Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine? (Q33895407) (← links)
• The appropriateness of routine medication treatment for schizophrenia. (Q33950877) (← links)
• Metformin for olanzapine‐induced weight gain: a systematic review and meta‐analysis (Q34161953) (← links)
• Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? (Q34183495) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (Q34315836) (← links)
• Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management (Q34543946) (← links)
• Body mass index and quality of life among outpatients with schizophrenia in Japan (Q34660592) (← links)
• Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis (Q34661011) (← links)
• Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. (Q35016170) (← links)
• Effects of sports participation on psychiatric symptoms and brain activations during sports observation in schizophrenia (Q35862424) (← links)
• Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorder (Q36074188) (← links)
• Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study (Q36075717) (← links)
• Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory (Q36201085) (← links)
• The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. (Q36240230) (← links)
• Design of the Lifestyle Interventions for severe mentally ill Outpatients in the Netherlands (LION) trial; a cluster randomised controlled study of a multidimensional web tool intervention to improve cardiometabolic health in patients with severe me (Q36317324) (← links)
• Interventions for the metabolic syndrome in schizophrenia: a review (Q36401248) (← links)
• Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain (Q36441507) (← links)
• Empirically Based Psychosocial Therapies for Schizophrenia: The Disconnection between Science and Practice (Q36848735) (← links)
• Metabolic syndrome in people with schizophrenia: a review. (Q37129646) (← links)
• Schizophrenia, obesity, and antipsychotic medications: what can we do? (Q37226376) (← links)
• Effectiveness of a psychosocial weight management program for individuals with schizophrenia (Q37257633) (← links)
• Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. (Q37516654) (← links)
• Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial (Q37633458) (← links)
• A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications (Q37998841) (← links)
• Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials (Q38132164) (← links)
• Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia (Q38656912) (← links)
• Sex Differences in Weight Loss among Veterans with Serious Mental Illness: Observational Study of a National Weight Management Program. (Q39640688) (← links)
• Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China (Q40022563) (← links)
• Antipsychotic-associated weight gain: management strategies and impact on treatment adherence (Q41546064) (← links)
• Qualitative descriptive study exploring schizophrenia and the everyday effect of medication-induced weight gain (Q43757239) (← links)
• Placebo-Controlled Trial of Atomoxetine for Weight Reduction in People with Schizophrenia Treated with Clozapine or Olanzapine (Q47383155) (← links)
• Effects of exercise training with traditional dancing on functional capacity and quality of life in patients with schizophrenia: a randomized controlled study (Q48055617) (← links)
• Pedometer walking plus motivational interviewing program for Thai schizophrenic patients with obesity or overweight: a 12-week, randomized, controlled trial (Q48129581) (← links)
• Low levels of physical activity in patients with severe mental illness (Q50758868) (← links)
• A Measure of Dysfunctional Eating-Related Cognitions in People with Psychotic Disorders (Q58174442) (← links)
• Interventions for preventing type 2 diabetes in adults with mental disorders in low and middle income countries (Q94266240) (← links)